Stoltz M - Search Results

1

Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors.

Schwartz GK, O'Reilly E, Ilson D, Saltz L, Sharma S, Tong W, Maslak P, Stoltz M, Eden L, Perkins P, Endres S, Barazzoul J, Spriggs D, Kelsen D. Schwartz GK, et al. Among authors: stoltz m. J Clin Oncol. 2002 Apr 15;20(8):2157-70. doi: 10.1200/JCO.2002.08.080. J Clin Oncol. 2002. PMID: 11956278 Clinical Trial.

2

Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma.

Schwartz GK, Ilson D, Saltz L, O'Reilly E, Tong W, Maslak P, Werner J, Perkins P, Stoltz M, Kelsen D. Schwartz GK, et al. Among authors: stoltz m. J Clin Oncol. 2001 Apr 1;19(7):1985-92. doi: 10.1200/JCO.2001.19.7.1985. J Clin Oncol. 2001. PMID: 11283131 Clinical Trial.

3

Phase I clinical trials of tezacitabine [(E)-2'-deoxy-2'-(fluoromethylene)cytidine] in patients with refractory solid tumors.

Rodriguez GI, Jones RE, Orenberg EK, Stoltz ML, Brooks DJ. Rodriguez GI, et al. Clin Cancer Res. 2002 Sep;8(9):2828-34. Clin Cancer Res. 2002. PMID: 12231523 Clinical Trial.

4

A pilot pharmacokinetic study of oral azacitidine.

Garcia-Manero G, Stoltz ML, Ward MR, Kantarjian H, Sharma S. Garcia-Manero G, et al. Among authors: stoltz ml. Leukemia. 2008 Sep;22(9):1680-4. doi: 10.1038/leu.2008.145. Epub 2008 Jun 12. Leukemia. 2008. PMID: 18548103 Clinical Trial.

5

A phase I study of the antimetabolite (E)-2'-fluoromethylene-2'-deoxycytidine (MDL 101,731) administered as a twice-weekly infusion.

Burtness B, Belker M, Stoltz M, Peccerillo KM, Lamb LA, Chmael SE, McKeon A, Clark MB, Winship J, Marsh JC, Pizzorno G, DeVita VT Jr. Burtness B, et al. Among authors: stoltz m. Cancer J. 2000 Sep-Oct;6(5):309-15. Cancer J. 2000. PMID: 11079170 Clinical Trial.

6

Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers.

Russell T, Stoltz M, Weir S. Russell T, et al. Among authors: stoltz m. Clin Pharmacol Ther. 1998 Dec;64(6):612-21. doi: 10.1016/S0009-9236(98)90052-2. Clin Pharmacol Ther. 1998. PMID: 9871426 Clinical Trial.

7

Pharmacokinetics and pharmacodynamics of the monoamine oxidase B inhibitor mofegiline assessed during a phase I dose tolerance trial.

Stoltz M, Reynolds D, Elkins L, Salazar D, Weir S. Stoltz M, et al. Clin Pharmacol Ther. 1995 Sep;58(3):342-53. doi: 10.1016/0009-9236(95)90252-X. Clin Pharmacol Ther. 1995. PMID: 7554709 Clinical Trial.

8

Effect of food on the bioavailability of fexofenadine hydrochloride (MDL 16455A).

Stoltz M, Arumugham T, Lippert C, Yu D, Bhargava V, Eller M, Weir S. Stoltz M, et al. Biopharm Drug Dispos. 1997 Oct;18(7):645-8. doi: 10.1002/(sici)1099-081x(199710)18:7<645::aid-bdd50>3.0.co;2-3. Biopharm Drug Dispos. 1997. PMID: 9330784 Clinical Trial. No abstract available.

9

Absorption, disposition and metabolism of di-isononyl phthalate (DINP) in F-344 rats.

McKee RH, El-Hawari M, Stoltz M, Pallas F, Lington AW. McKee RH, et al. Among authors: stoltz m. J Appl Toxicol. 2002 Sep-Oct;22(5):293-302. doi: 10.1002/jat.861. J Appl Toxicol. 2002. PMID: 12355558

10

Patient-derived Colonoids From Disease-spared Tissue Retain Inflammatory Bowel Disease-specific Transcriptomic Signatures.

Karakasheva TA, Zhou Y, Xie HM, Soto GE, Johnson TD, Stoltz MA, Roach DM, Nema N, Umeweni CN, Naughton K, Dolinsky L, Pippin JA, Wells AD, Grant SFA, Ghanem L, Terry N, Muir AB, Hamilton KE. Karakasheva TA, et al. Among authors: stoltz ma. Gastro Hep Adv. 2023;2(6):830-842. doi: 10.1016/j.gastha.2023.05.003. Epub 2023 May 25. Gastro Hep Adv. 2023. PMID: 37736163 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

110 results

Search Page